Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609011 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
A Phase 1 study, sponsored by Myrexis.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00609011 is a Phase 1 study that has completed, run by Myrexis. The registered enrollment target is 22 participants.
The verdict
NCT00609011, a Phase 1 study, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with temozolomide.
Interventions
- DRUG MPC-6827 + Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00609011
The ClinicalTrials.gov registry entry for NCT00609011 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myrexis, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MPC-6827 + Temozolomide is the first listed.
NCT00609011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00609011 about?
NCT00609011 is a clinical study titled "Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma". This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxi...
What is the current status of trial NCT00609011?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-03. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00609011?
The interventions under investigation include: MPC-6827 + Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00609011?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.